Tandem Diabetes Care (BSP:T2ND34) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:T2ND34 Tandem Diabetes Care Inc BSP:T2ND34
49 GF Score
Price R$5.98
GF Value R$8.36
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Tandem Diabetes Care Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

BSP:T2ND34
49GF Score
Tandem Diabetes Care Inc BSP:T2ND34
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Tandem Diabetes Care (BSP:T2ND34) Overvalued in 2026?

Based on GuruFocus' analysis, Tandem Diabetes Care stock appears to be undervalued. The current stock price of R$5.98 is trading 28.5% below its estimated GF Value™ of R$8.36. GuruFocus considers Tandem Diabetes Care to be Modestly Undervalued.

Key valuation signals for BSP:T2ND34:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: R$8.36 vs. price of R$5.98 (28.5% below fair value)
  • GF Score™: 49/100 with 5 warning signs

No single metric tells the full story. See the BSP:T2ND34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Tandem Diabetes Care Business Description

Other Exchanges TNDM:USA0M0F:UKTD5A:Germany
Address 12400 High Bluff Drive, San Diego, CA, USA, 92130
Tandem Diabetes Care Inc. is a medical device company that designs, develops, and commercializes insulin delivery systems for people with diabetes. Its flagship product is the t:slim X2 insulin pump, which integrates with continuous glucose monitoring systems and automated insulin dosing software, including its Control-IQ technology. The company also offers the smaller Mobi pump and has been developing the Sigi tubeless patch pump. Tandem sells durable pumps and recurring consumables such as infusion sets and cartridges, generating a significant portion of revenue from repeat purchases. Its primary market is the United States, which accounts for the majority of sales, with additional revenue from other developed countries. Customers include individuals with type 1 and type 2 diabetes, healthcare providers, and diabetes clinics. The company operates through direct sales and distributors, deriving revenue from both hardware and disposable supplies.
49GF Score

Get the complete analysis for BSP:T2ND34

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$5.98
Price
R$8.36
GF Value